Irving-based McKesson Corp. announced that Dr. Deborah Dunsire has been elected a director and member of the compensation and talent committee and finance committee.
“We’re pleased to welcome Deborah to the McKesson board,” Donald Knauss, McKesson’s independent board chair, said in a statement. “She is a highly respected healthcare industry leader with a proven track record of leading large, complex organizations as both a CEO and a board member. Her unique perspective, clinical background and expertise within the pharmaceutical and oncology arenas will add great value to McKesson and its purpose of Advancing Health Outcomes for All®.”
McKesson said that Dunsire joins the board with more than 30 years of experience leading large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.
Most recently, Dunsire retired from her role as president and CEO of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases. Before that, Dunsire held executive leadership roles for several pharmaceutical companies including XTuit Pharmaceuticals, FORUM Pharmaceuticals, Millennium: The Takeda Oncology Co., and Millennium Pharmaceuticals.
Dunsire started her career as a primary care physician in Johannesburg, South Africa.
She currently serves on the boards of directors of Syros Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc. She received her medical degree from the University of Witwatersrand in Johannesburg.
Board members Linda Mantia, who is no longer independent, and Susan Salka, who has served on the board for almost 10 years, will not be standing for re-election at the 2024 Annual Meeting of Shareholders, the company said. Upon the election of all proposed director nominees at the Annual Meeting, the size of the board will be reduced to 11 members, 10 of whom are independent.
A Fortune 500 company, McKesson is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
"Since data is crucial for maintaining ongoing DEIB initiatives and dedication, Kanarys leads the way in establishing quantifiable DEIB strategies, thanks to its data-centric methodology aimed at creating a fairer future for all work settings," says Google CDO and Kanary's Board Member Melonie Parker.
-
Arthur Angulo and Alan Gardner have been appointed to the Comerica Inc. board of directors, the Dallas-based banking company announced. "The experience and expertise that Art and Alan bring from their respective fields make them highly valuable additions to our board of directors," Curt Farmer, chairman, president and CEO of Comerica Inc., said in a statement. "I look forward to working with them and continuing Comerica's efforts to deliver growth for our shareholders, colleagues and communities." Angulo is managing director of Promontory Financial Group, a business unit of International Business Machines Corp.'s consulting business segment and as an IBM partner.…
-
Nehal Raj and Jeffrey Rhodes serve as co-managing partners of TPG Capital, the firm’s U.S. and European private equity business, and Jim Baumgarten as co-managing partner of TPG Angelo Gordon, the firm’s diversified credit and real estate investing platform.
-
Irving-Based McKesson Launches Project To Address 'Pharmacy Deserts' in Underserved U.S. CommunitiesLow-income residents without access to vehicles often find themselves more than a mile from much-needed medicines and prescription drugs. Project Oasis, a new McKesson initiative, aims to help address that.
-
Emmett T. Cunningham is a senior partner at HealthQuest Capital Management and co-founder and executive chairman of Eyconis, a spinout of Ascendis Pharma.
